LXi REIT swaps two care homes for a Stobart industrial facility – After an unsolicited approach, LXi has sold two care homes in Leicestershire let to Prime Life to a UK pension fund for £19.0 million. They say that this: reflects a low exit yield of 5.25%, which compares favourably to the acquisition yield of 6.50% […]
Henderson Far East to shift to UK – Henderson Far East Income has published proposals to migrate to UK tax residence and apply for UK investment trust status. The fund currently earns investment income from a diversified portfolio of investments with exposure to the Asia Pacific region, much of which is subject to overseas withholding […]
NextEnergy Solar adds another ten plants – NextEnergy Solar Fund has announced the signing and completion of a share purchase agreement for the acquisition of ten operating solar plants with a total installed capacity of 46.6 MWp. The plants were acquired from a single counterparty, from which the company has previously acquired five solar power […]
John Laing Environmental commits to Vulcan plant expansion – John Laing Environmental Assets Group has announced a further investment in the Vulcan Renewables anaerobic digestion (AD) plant. The investment consists of provision of funding of c.£8.5m to significantly expand the AD plant’s biomethane generating capacity. Vulcan Renewables was acquired in August 2017. The plant is located […]
Hansa Trust has a better year – Hansa Trust has reported its results for the year ended 31 March 2018. Over this period, while inflation was 2.5% and the return on the MSCI All Countries World Index was 2.6%, it delivered a return on NAV of 6.3% and returns to shareholders of 16.5% on its ordinary […]
US biotech IPO market faces key test after record five pricings The currently buoyant US market for biotech new issues faces a key test, after a record five companies priced Nasdaq offerings in a single day. The success of those listings in the immediate after-market is likely to be important gauge of the overall health […]
Reconstruction Capital II returned €17.4m to its shareholders- In its annual report for the year ending 31 December 2017, Reconstruction Capital II (RC2) reported that its NAV decreased by 31.8% from €0.3670 per share to €0.2504 per share. This was because it returned €17.4m to Shareholders over the year. The majority of this was the proceeds of the sale of Albalact S.A. […]
Dunedin Smaller merging with Standard Life UK Smaller – The board of Dunedin Smaller Companies Investment Trust has undertaken a strategic review of the company and its position in the UK smaller companies sector. The Board is aware that the company’s size and the secondary market liquidity in its shares make it challenging to attract […]
Syncona accelerates investment in gene therapy portfolio LSE-listed biotech VC fund Syncona (SYNC) has made a significant investment in three of its portfolio companies involved in developing gene therapies, with staged commitments of £85m ($112m) to Freeline Therapeutics, $35m to SwanBio and $12m to Orbit Biomedical. Freeline, which was spun out from University College London (UCL) in 2015, is […]
Alexion files for key drug with priority review voucher Trust favourite Alexion Pharmaceuticals (Nasdaq: ALXN) yesterday confirmed it had made a US regulatory submission for approval of ALXN1210, its long-acting C5 complement inhibitor, for the treatment of the ultra-rare condition of paroxysmal nocturnal hemoglobinuria (PNH). Alexion is a cornerstone holding for both the OrbiMed-managed Biotech Growth Trust […]
